company background image
CSBR

Champions OncologyNasdaqCM:CSBR Stock Report

Last Price

US$8.03

Market Cap

US$108.5m

7D

1.9%

1Y

-28.6%

Updated

16 Jan, 2022

Data

Company Financials +
CSBR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance3/6
Financial Health6/6
Dividends0/6

CSBR Stock Overview

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States.

Rewards

Trading at 72.7% below our estimate of its fair value

Earnings are forecast to grow 126.68% per year

Became profitable this year

Risk Analysis

No risks detected for CSBR from our risk checks.

Champions Oncology Competitors

Eurofins Scientific

ENXTPA:ERF

€17.8b

Price History & Performance

Summary of all time highs, changes and price drops for Champions Oncology
Historical stock prices
Current Share PriceUS$8.03
52 Week HighUS$14.68
52 Week LowUS$7.75
Beta0.97
1 Month Change-0.74%
3 Month Change-20.50%
1 Year Change-28.56%
3 Year Change-19.62%
5 Year Change117.62%
Change since IPO-33.08%

Recent News & Updates

Oct 14
We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

The underwhelming share price performance of Champions Oncology, Inc. ( NASDAQ:CSBR ) in the past three years would...

Shareholder Returns

CSBRUS Life SciencesUS Market
7D1.9%-1.8%-0.5%
1Y-28.6%9.6%13.7%

Return vs Industry: CSBR underperformed the US Life Sciences industry which returned 9.6% over the past year.

Return vs Market: CSBR underperformed the US Market which returned 13.7% over the past year.

Price Volatility

Is CSBR's price volatile compared to industry and market?
CSBR volatility
CSBR Average Weekly Movement6.4%
Life Sciences Industry Average Movement8.7%
Market Average Movement6.6%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: CSBR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: CSBR's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1985194Ronnie Morrishttps://www.championsoncology.com

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized cancer care based upon the implantation of human tumors in immune-deficient mice.

Champions Oncology Fundamentals Summary

How do Champions Oncology's earnings and revenue compare to its market cap?
CSBR fundamental statistics
Market CapUS$108.52m
Earnings (TTM)US$391.00k
Revenue (TTM)US$44.42m

277.6x

P/E Ratio

2.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CSBR income statement (TTM)
RevenueUS$44.42m
Cost of RevenueUS$21.47m
Gross ProfitUS$22.94m
ExpensesUS$22.55m
EarningsUS$391.00k

Last Reported Earnings

Oct 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.029
Gross Margin51.66%
Net Profit Margin0.88%
Debt/Equity Ratio0%

How did CSBR perform over the long term?

See historical performance and comparison

Valuation

Is Champions Oncology undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CSBR ($8.03) is trading below our estimate of fair value ($29.44)

Significantly Below Fair Value: CSBR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CSBR is poor value based on its PE Ratio (277.6x) compared to the US Life Sciences industry average (39.9x).

PE vs Market: CSBR is poor value based on its PE Ratio (277.6x) compared to the US market (17.4x).


Price to Earnings Growth Ratio

PEG Ratio: CSBR is poor value based on its PEG Ratio (2.2x)


Price to Book Ratio

PB vs Industry: CSBR is overvalued based on its PB Ratio (13.4x) compared to the US Life Sciences industry average (3.3x).


Future Growth

How is Champions Oncology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

126.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CSBR's forecast earnings growth (126.7% per year) is above the savings rate (2%).

Earnings vs Market: CSBR's earnings (126.7% per year) are forecast to grow faster than the US market (13% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CSBR's revenue (17.2% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: CSBR's revenue (17.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CSBR's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Champions Oncology performed over the past 5 years?

59.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CSBR has high quality earnings.

Growing Profit Margin: CSBR became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: CSBR has become profitable over the past 5 years, growing earnings by 59.9% per year.

Accelerating Growth: CSBR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CSBR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (72.2%).


Return on Equity

High ROE: CSBR's Return on Equity (4.8%) is considered low.


Financial Health

How is Champions Oncology's financial position?


Financial Position Analysis

Short Term Liabilities: CSBR's short term assets ($13.7M) exceed its short term liabilities ($12.5M).

Long Term Liabilities: CSBR's short term assets ($13.7M) exceed its long term liabilities ($8.8M).


Debt to Equity History and Analysis

Debt Level: CSBR is debt free.

Reducing Debt: CSBR had no debt 5 years ago.

Debt Coverage: CSBR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CSBR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Champions Oncology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CSBR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CSBR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CSBR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CSBR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CSBR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Ronnie Morris (55 yo)

5yrs

Tenure

US$775,000

Compensation

Dr. Ronnie Morris, M.D. has been Chief Executive Officer at Champions Oncology, Inc. since January 31, 2017 and its President since 2021. Dr. Morris previously served as the President and a Director of Cha...


CEO Compensation Analysis

Compensation vs Market: Ronnie's total compensation ($USD775.00K) is above average for companies of similar size in the US market ($USD578.13K).

Compensation vs Earnings: Ronnie's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CSBR's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: CSBR's board of directors are seasoned and experienced ( 10.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Champions Oncology, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Champions Oncology, Inc.
  • Ticker: CSBR
  • Exchange: NasdaqCM
  • Founded: 1985
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$108.525m
  • Shares outstanding: 13.51m
  • Website: https://www.championsoncology.com

Number of Employees


Location

  • Champions Oncology, Inc.
  • One University Plaza
  • Suite 307
  • Hackensack
  • New Jersey
  • 7601
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/16 23:07
End of Day Share Price2022/01/14 00:00
Earnings2021/10/31
Annual Earnings2021/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.